BioCryst reports full year financial results

At the announcement of the BioCryst Pharmaceuticals, Inc.  financial results for 2017 President & CEO Jon P. Stonehouse said:

“Our team made significant progress in 2017 and we are off to a strong start in 2018. We are keenly focused on continuing that momentum by advancing our pipeline, adding additional programs and driving our BCX7353 oral prophylactic program toward approval and launch. We are on track to report top-line results from the APeX-2 pivotal trial of BCX7353.”

Mr. Stonehouse continued, “In January, we announced our proposed merger with Idera Pharmaceuticals, Inc. that we believe will build greater and more sustainable value for the benefit of stockholders as well as patients with rare diseases beyond what we could achieve alone. The BioCryst Board determined this combination was compelling from both a strategic and financial perspective following a careful evaluation of a range of strategies to enhance long-term stockholder value. The transaction will create a leading rare disease company with a robust pipeline including two promising Phase 3 programs and combines synergistic discovery engines that will not only expand the number of rare diseases we can target but create meaningful opportunities for differentiation in the market through joint small molecule and oligo treatments. Importantly, joining with Idera will also enable us to achieve cost synergies and increase our financial strength and flexibility.”
(Source: BioCryst)

2018-03-01T22:30:10+01:00February 28, 2018|HAEi News|